TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Galderma has agreed to acquire all of ZO Skin Health in an all-cash transaction valued at US$1.5 billion. The deal would expand Galderma’s professional skincare portfolio and is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approval.
Galderma has agreed to acquire ZO Skin Health in an all-cash deal valuing the physician-dispensed skincare company at US$1.5 billion. The acquisition would give Galderma full ownership of the US brand and broaden its skincare offering alongside Cetaphil and Alastin; completion remains subject to regulatory approval.
The agreement covers 100 percent of ZO Skin Health, which Galderma will acquire from its shareholders, including Blackstone Tactical Opportunities and the Obagi family. The deal is structured as an all-cash transaction. The companies have not provided further financial terms in the supplied announcement.
ZO Skin Health was founded by dermatologist Dr. Zein Obagi. It recorded approximately US$330 million in net sales in the 12 months to June 2026, according to the source report. The business sells in more than 40 countries and serves a network of over 16,500 physician, medical spa and online accounts.
Galderma says the brand will complement its existing Cetaphil and Alastin businesses. It plans to increase commercial investment to support ZO Skin Health’s future growth. The source report does not specify how much will be invested or describe changes to the brand’s products, workforce or distribution arrangements.
How ZO Expands Galderma’s Skincare Business
The purchase would add a sizeable physician-dispensed skincare business to Galderma’s portfolio and deepen its links with dermatologists and aesthetic practitioners. ZO Skin Health’s account network and international reach could give Galderma additional channels for selling professional skincare products and opportunities to distribute the brand in more markets.
The acquisition also connects Galderma’s skincare business more closely with its aesthetic treatments and injectable business. That combination may create opportunities for cross-category growth and product development, as the company says. Those are potential benefits, not guaranteed results: the announcement does not quantify expected cost savings, revenue gains or the deal’s effect on earnings.
For customers and practitioners, the practical effect will depend on how Galderma manages the brand after closing. The deal announcement does not say whether product lines, pricing, account relationships or commercial policies will change.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
ZO’s Role in Galderma’s Portfolio
Galderma already owns Cetaphil, a skincare brand, and Alastin, which serves the professional skincare market. The proposed purchase adds ZO Skin Health, a brand founded by a dermatologist and sold through physician, medical spa and online accounts. Galderma describes the acquisition as a way to strengthen its position in professional skincare and medical aesthetics.
The transaction is a proposed acquisition rather than a completed change of ownership. Galderma’s stated timetable places closing in the fourth quarter of 2026 or early 2027, depending in part on regulatory approval. Until the deal closes, ZO Skin Health remains owned by its current shareholders.
“The acquisition will complement Galderma’s existing Cetaphil and Alastin brands.”
— Galderma, as reported by Global Cosmetics News
Approval and Integration Details Remain Open
The acquisition has not closed. It still requires regulatory approval, and the announcement does not identify the regulators involved or describe any review timetable. Galderma expects completion in the fourth quarter of 2026 or early 2027, but that schedule could change.
Other details remain undisclosed in the source material, including the precise allocation of the purchase price, the scope of planned commercial investment and whether Galderma expects changes to ZO Skin Health’s leadership, staffing, products or sales channels. The stated sales figure covers the 12 months to June 2026; the source report provides no comparison period or growth rate.
Regulatory Review Sets the Next Milestone
The next major milestone is regulatory review. Galderma expects the acquisition to close in Q4 2026 or early 2027, subject to approval. The companies have not announced an exact closing date or further interim milestones.
After closing, Galderma says it plans to increase commercial investment in ZO Skin Health. Further disclosures may clarify how the company intends to support distribution, product development and the brand’s existing practitioner and online accounts.
Key Questions
How much is Galderma paying for ZO Skin Health?
The deal is valued at US$1.5 billion and is structured as an all-cash acquisition. Further financial terms were not provided in the source material.
Who currently owns ZO Skin Health?
Galderma is acquiring the company from its shareholders, including Blackstone Tactical Opportunities and the Obagi family. The transaction has not yet closed.
When is the acquisition expected to close?
Galderma expects completion in the fourth quarter of 2026 or early 2027, subject to regulatory approval. No exact closing date has been announced.
What does ZO Skin Health sell, and where does it operate?
ZO Skin Health is a US-based, physician-dispensed skincare brand founded by dermatologist Dr. Zein Obagi. The source report says it operates in more than 40 countries through over 16,500 physician, medical spa and online accounts.
Will the deal change ZO Skin Health products or customer access?
The announcement does not say whether products, pricing, account relationships or distribution will change. Galderma has said it plans increased commercial investment, but has not detailed how it will be used.
Source: rss
